Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Equivalents (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Cash & Equivalents data on record, last reported at $112.3 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 61.48% year-over-year to $112.3 million; the TTM value through Dec 2025 reached $112.3 million, up 61.48%, while the annual FY2025 figure was $112.3 million, 61.48% up from the prior year.
  • Cash & Equivalents reached $112.3 million in Q4 2025 per TNGX's latest filing, up from $58.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $207.3 million in Q3 2021 and bottomed at $51.6 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $83.9 million, with a median of $66.2 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 212683.58% in 2021, then plummeted 58.65% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $145.0 million in 2021, then plummeted by 58.65% to $60.0 million in 2022, then increased by 10.7% to $66.4 million in 2023, then grew by 4.74% to $69.5 million in 2024, then skyrocketed by 61.48% to $112.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $112.3 million in Q4 2025, $58.4 million in Q1 2025, and $69.5 million in Q4 2024.